Logo Medical Science Monitor Basic Research

Call: 1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research

LDL-apheresis and its effects on the lipid profile and plasma fibrinogen level in patients with refractory hypercholesterolemia-preliminary report

Ewa Konduracka, Wiesława Piwowarska, Aldona Dembińska-Kieć, Stanisław Bartuś, Łukasz Partyka, Jadwiga Hartwich, Iwona Gołąbek, Izabella Pietrzak, Jerzy Sadowski, Dariusz Dudek

Med Sci Monit 1998; 4(6): CR938-941 :: ID: 451727

Abstract

LDL-apheresis is a method for the extracorporeal removal of LDL-cholesterol and its modified forms in patients with refractory hypercholesterolemia, who are unresponsive towards standard lipid lowering diets as well as drugs. The aim of this study was to analyse the influence of LDL apheresis on blood lipid profile and plasma fibrinogen concentration changes in patients with ischemic heart disease and refractory hypercholesterolemia. The study group comprised six men, aged between 39-54 who underwent coronary angiography and invasive treatment (3-PTCA, 3-CABG). The patients mean total cholesterol level was 7.7 mmol/l and the mean LDL-cholesterol level was 5.7 mmol/l despite a diet and one months treatment with simvastatine (20- 40mg/day). The mean plasma fibrinogen level prior to apheresis was 3.7g/l. Treatment with LDL-apheresis was introduced, two days before the revascularization procedure and continued for a period of one to three months following PTCA or CABG, in order to maintain the LDL-cholesterol level below 2.5 mmol/l. Results: A single LDL apheresis caused reduction of the mean total cholesterol level by 53% and mean LDL-cholesterol level by 65%. Examination of the LDL fraction revealed an increase of resistance towards oxidation performed ex vivo. We also observed a transient decrease in the mean plasma fibrinogen level (by 21%). Conclusions: LDL apheresis is a safe and effective method in the treatment of refractory hypercholesterolemia. Continued therapy with LDL-apheresis decreases coronary artery disease risk factors such as hypercholesterolemia and hyperfibrinogenemia.

Keywords: LDL-apheresis, refractory hypercholesterolemia

Comments

Most Viewed Current Articles

31 Dec 1969 : Original article  

Outcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...

DOI :10.12659/MSMBR.920449

Med Sci Monit Basic Res 2020; 26:e920449

31 Dec 1969 : Original article  

Analysis of Psychological and Sleep Status and Exercise Rehabilitation of Front-Line Clinical Staff in the ...

DOI :10.12659/MSMBR.924085

Med Sci Monit Basic Res 2020; 26:e924085

31 Dec 1969 : Review article  

A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against...

DOI :10.12659/MSMBR.929207

Med Sci Monit Basic Res 2021; 27:e929207

31 Dec 1969 : Clinical Research  

Effects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...

DOI :10.12659/MSMBR.925264

Med Sci Monit Basic Res 2020; 26:e925264

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor Basic Research eISSN: 2325-4416
Medical Science Monitor Basic Research eISSN: 2325-4416